IFHA Issues Resolution on Altrenogest

[Wandering Eyes]

During the Oct. 8 meeting, the International Federation of Horseracing Authorities executive council considered recent issues which have arisen from the administration of altrenogest-containing products, including issues relate to the presence of the anabolic androgenic steroids (AAS) trendione, trenbolone, and epitrenbolone in samples taken from horses that have been administered altrenogest-containing products.
Considering a detailed report from technical committees on the issue, the executive council concluded there is no evidence to support that trendione, trenbolone and epitrenbolone are endogenous substances, and in these circumstances, there is no basis upon which a threshold may legitimately be applied to the detection of these substances. The council also noted that, given trendione, trenbolone and epitrenbolone as AAS are classified as major doping agents, a screening limit cannot legitimately be applied to them.
Having considered those issues, the executive council agreed that a core principle set out in Article 6 of the IABRW (including Article 6A and 6E) must be applied. That principle dictates that horses in training and on race day must be free from major doping agents, including trendione, trenbolone and epitrenbolone. Also, a zero-tolerance approach to the detection of these major doping agents must inform racing’s approach to the matter, irrespective of the potential cause of their presence.
Therefore, in the event a major doping agent, including trendione, trenbolone or epitrenbolone, is detected in a sample at any level, a prohibited substance violation arises and must be acted upon by a racing authority.

The executive council resolved as follows:
• Applying the principles underlying Article 6 of the IABRW, where the substances trendione, trenbolone and/or epitrenbolone are detected in a sample taken at any time from a horse, that detection must be treated as a prohibited substance violation.
• This position shall apply irrespective of whether the detection was caused by, or is suspected to have been caused by, the administration of an altrenogest-containing product.

For additional information, please contact: Andrew Chesser, IFHA Secretary General, achesser@jockeyclub.com .

The post IFHA Issues Resolution on Altrenogest appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

View the full article